T-cell replete cord vs comparator cohort NRM. T-replete CB was associated with significantly higher nonrelapse mortality (HR, 2.05 [95% CI, 1.05-4.01]; P =.04) by univariable analysis with 2-year cumulative incidence of 12.3% (95% CI, 7.3-20.4) for the T-replete cord cohort vs 7.2% (95% CI, 4.6-11.2) for the comparator group.